RIGI and cancer: As P97-NPL4 pathway has been suggested to be closely associated with inhibition of RIG-I-mediated innate immune signaling pathway 66 and maintenance of regulatory T cell development 67, it is possible that DSF/Cu targets P97-NPL4 pathway to activate innate immunity and enhance anti-cancer immunity.